Subtopic Deep Dive

Extended-Spectrum β-Lactamases
Research Guide

What is Extended-Spectrum β-Lactamases?

Extended-spectrum β-lactamases (ESBLs) are β-lactamase enzymes produced by bacteria that hydrolyze third-generation cephalosporins and aztreonam but are inhibited by clavulanic acid.

ESBLs primarily occur in Enterobacteriaceae and derive from mutations in genes for TEM, SHV, and CTX-M enzymes (Paterson and Bonomo, 2005, 3345 citations). They cause resistance to key antibiotics used for common infections. Over 250 studies document their global spread since the 1980s (Bradford, 2001, 2561 citations).

Curated Papers

Key Challenges

Why It Matters

ESBL-producing bacteria elevate morbidity and healthcare costs from urinary tract and bloodstream infections, contributing to 48,700 annual U.S. deaths from resistance (Centers for Disease Control and Prevention, 2019, 5814 citations). They drive hospital outbreaks, as seen in National Healthcare Safety Network data on device-associated infections (Hidrón et al., 2008, 3739 citations). New ESBL variants like NDM-1 emerged in India, Pakistan, and the UK, accelerating global transmission (Kumarasamy et al., 2010, 2887 citations). Tools like ResFinder identify these genes in sequenced isolates (Zankari et al., 2012, 4974 citations).

Key Research Challenges

Molecular Epidemiology Tracking

Mapping ESBL gene spread across regions requires integrating genomic and clinical data. Variants like CTX-M evolve rapidly, complicating surveillance (Paterson and Bonomo, 2005). Zankari et al. (2012) introduced ResFinder, but real-time updates lag behind outbreaks.

Diagnostic Detection Limits

Standard tests miss low-level ESBL producers due to clavulanate inhibition variability. Bradford (2001) detailed phenotypic confirmation needs. Clinical labs struggle with mixed resistance mechanisms in Enterobacteriaceae.

Therapeutic Options Exhaustion

ESBLs limit cephalosporin use, pushing reliance on carbapenems and fueling further resistance. Levy and Marshall (2004) outlined global causes including overuse. Kumarasamy et al. (2010) reported NDM-1 cases resistant to all but colistin.

Essential Papers

Antibiotic resistance threats in the United States, 2019

Centers for Disease Control and Prevention (U.S.) · 2019 · 5.8K citations

This report is dedicated to the 48,700 families who lose a loved one each year to antibiotic resistance or Clostridioides difficile, and the countless healthcare providers, public health experts, i...

Identification of acquired antimicrobial resistance genes

Ea Zankari, Henrik Hasman, Salvatore Cosentino et al. · 2012 · Journal of Antimicrobial Chemotherapy · 5.0K citations

A web server providing a convenient way of identifying acquired antimicrobial resistance genes in completely sequenced isolates was created. ResFinder can be accessed at www.genomicepidemiology.org...

Antibacterial resistance worldwide: causes, challenges and responses

Stuart B. Levy, Bonnie Marshall · 2004 · Nature Medicine · 4.0K citations

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

Alicia Hidrón, Jonathan R. Edwards, Jean B. Patel et al. · 2008 · Infection Control and Hospital Epidemiology · 3.7K citations

Objective. To describe the frequency of selected antimicrobial resistance patterns among pathogens causing device-associated and procedure-associated healthcare-associated infections (HAIs) reporte...

Extended-Spectrum β-Lactamases: a Clinical Update

David L. Paterson, Robert A. Bonomo · 2005 · Clinical Microbiology Reviews · 3.3K citations

SUMMARY Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by c...

Global increase and geographic convergence in antibiotic consumption between 2000 and 2015

Eili Klein, Thomas P. Van Boeckel, Elena Martínez et al. · 2018 · Proceedings of the National Academy of Sciences · 3.0K citations

Significance Antibiotic resistance, driven by antibiotic consumption, is a growing global health threat. Our report on antibiotic use in 76 countries over 16 years provides an up-to-date comprehens...

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

Kanimozhi Kumarasamy, Mark A. Toleman, Timothy R. Walsh et al. · 2010 · The Lancet Infectious Diseases · 2.9K citations

Reading Guide

Foundational Papers

Start with Paterson and Bonomo (2005) for ESBL clinical definition and mechanisms, then Bradford (2001) for epidemiology. Zankari et al. (2012) introduces ResFinder for gene identification.

Recent Advances

Centers for Disease Control and Prevention (2019) quantifies U.S. threats; Klein et al. (2018) maps global consumption driving ESBLs; Larsson and Flach (2021) examines environmental spread.

Core Methods

Phenotypic disk-diffusion with clavulanate; genomic via ResFinder web server (Zankari et al., 2012); epidemiological modeling from CDC surveillance (Hidrón et al., 2008).

How PapersFlow Helps You Research Extended-Spectrum β-Lactamases

Discover & Search

Research Agent uses searchPapers and exaSearch to find ESBL literature like 'Extended-Spectrum β-Lactamases: a Clinical Update' by Paterson and Bonomo (2005), then citationGraph reveals 3345 citing works on CTX-M spread. findSimilarPapers clusters related epidemiology studies from Zankari et al. (2012) ResFinder tool.

Analyze & Verify

Analysis Agent applies readPaperContent to parse ESBL enzyme kinetics from Bradford (2001), then runPythonAnalysis with pandas to quantify resistance rates from Hidrón et al. (2008) datasets. verifyResponse via CoVe cross-checks claims against GRADE grading, verifying ESBL morbidity impacts (Centers for Disease Control and Prevention, 2019).

Synthesize & Write

Synthesis Agent detects gaps in ESBL therapeutic studies post-Kumarasamy et al. (2010), flags contradictions in prevalence data. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Levy and Marshall (2004), with latexCompile for publication-ready output and exportMermaid for resistance gene flow diagrams.

Use Cases

"Analyze ESBL prevalence trends from CDC data using Python."

Research Agent → searchPapers(CDC 2019) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of 48,700 deaths) → matplotlib graph of U.S. resistance rates.

"Write LaTeX review on CTX-M ESBL evolution."

Synthesis Agent → gap detection(Paterson 2005) → Writing Agent → latexEditText(draft sections) → latexSyncCitations(Bradford 2001, Zankari 2012) → latexCompile(PDF review with figures).

"Find GitHub repos implementing ResFinder for ESBL detection."

Research Agent → searchPapers(Zankari 2012) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(active forks with ESBL gene prediction code).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ ESBL papers: searchPapers → citationGraph → GRADE grading → structured report on global spread (Klein et al., 2018). DeepScan applies 7-step analysis with CoVe checkpoints to verify NDM-1 epidemiology from Kumarasamy et al. (2010). Theorizer generates hypotheses on ESBL-environment links from Larsson and Flach (2021).

Try Doxa for Extended-Spectrum β-Lactamases Research

Frequently Asked Questions

What defines an ESBL enzyme?

ESBLs hydrolyze third-generation cephalosporins and aztreonam but are inhibited by clavulanic acid, deriving from TEM, SHV, or CTX-M genes (Paterson and Bonomo, 2005).

What are key ESBL detection methods?

Phenotypic tests use clavulanate synergy; genomic tools like ResFinder identify genes in sequenced isolates (Zankari et al., 2012; Bradford, 2001).

Which papers define ESBL research?

Paterson and Bonomo (2005, 3345 citations) provide clinical updates; Bradford (2001, 2561 citations) covers epidemiology and detection.

What are open problems in ESBL research?

Real-time surveillance of evolving variants like NDM-1 and environmental reservoirs remain unsolved (Kumarasamy et al., 2010; Larsson and Flach, 2021).